[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608182":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"DEB-TACE",null,"Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Salvage Therapy for Recurrent and Refractory Diffuse Large B-Cell Lymphoma with Bulky Lesions",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Xiaoquan ji","CONTACT","+8618159117171","jxqwd0901@163.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350001","China","CN",{"type":28,"coordinates":29},"Point",[30,31],119.30611,26.06139,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ting YANG","Professor","100608182","drug-eluting-bead-based-transarterial-chemoembolization-deb-tace-as-a-local-salvage-therapy-for-large-lesions-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-100608182",false,"NCT07198230","Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age 18 to 75 years; (2) Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); (3) Recurrence or treatment resistance following multiple therapeutic regimens (e.g., chemotherapy, immunotherapy, targeted therapy), with at least one clearly defined bulky lesion (maximum diameter ≥5 cm or imaging evidence of bulky lesion); (4) Imaging studies (CT, MRI, or PET-CT) confirm rich blood supply to the lesion, making it suitable for transarterial interventional therapy; (5) History of favorable response to doxorubicin-based agents during prior systemic therapy; (6) ECOG performance status ≤ 2; (7) Blood counts, hepatic and renal function, and coagulation parameters meet the following criteria:\n\n  * Platelet count ≥ 30 × 10\\^9\u002FL;\n  * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the ULN;\n  * Serum creatinine ≤ 2.5 times the upper limit of normal (ULN);\n  * Prothrombin time international normalized ratio (INR) ≤ 1.5. (8) The patient has previously undergone at least one DEB-TACE treatment at this institution.\n\nExclusion Criteria:\n\n* (1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or other serious comorbidities rendering them unable to tolerate interventional therapy; (2) Patients with active or uncontrolled severe infections; (3) Patients with severe coagulation disorders or bleeding tendencies; (4) Pregnant or lactating women, or patients planning pregnancy during the study period; (5) Allergy or contraindications to drug-eluting microsphere materials or chemotherapy drugs; (6) Psychiatric disorders or cognitive impairment preventing treatment compliance and follow-up; (7) Other conditions deemed unsuitable for study participation by the investigator.","ALL","18 Years","75 Years",{"count":49,"type":50},10,"ESTIMATED","OBSERVATIONAL","Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.",[54,55,56],"Diffuse Large B-Cell Lymphoma","Relapsed and Refractory","Transarterial Chemoembolization","2025-11-15",{"date":59,"type":60},"2025-11-18","ACTUAL",{"date":62,"type":60},"2025-03-01",{"date":64,"type":50},"2027-09-01",{"name":37,"class":6},1]